Transcript Dementias and Neurodegenerative Diseases

Dementias and Neurodegenerative Diseases
Research Network
Clinical trials with DeNDRoN in the
North East
Dr Margaret Piggott
Data and Communications Manager
www.dendron.nihr.ac.uk/northeast
Dementias and Neurodegenerative
Diseases Research Network
Based at St Nicholas Hospital
and Institute for Ageing and Health in Newcastle
Team members also in Tees, Esk and Wear Valley NHS Trust
and County Durham and Darlington NHS Trust
www.dendron.org.uk
Where we fit in…
Supports
facilities for
research
Commissions and funds NHS
and social care research
(e.g. Biomedical
Research Units)
Trains and
develops
researchers







Cancer
Dementia and
Neurodegenerative
Diseases
Diabetes
Medicines for Children
Mental Health
Stroke
Primary Care
Comprehensive
Dementias and Neurodegenerative Diseases
Research Network
Research arm of NHS
Facilitate studies for
prevention, diagnosis,
treatment
• Flexible
• Experienced
• Trained research support
www.dendron.org.uk
Dementias and Neurodegenerative
Diseases Research Network
Range of studies in dementia –
Clinical Trial of an Investigational
Medicinal Product (CTIMPs)
• DOMINO
• HTA-SADD
• MAIN-AD
• Scarlet Road
• Servier
Observational, Investigative and
Neuropsychiatric Studies
• DEMO-POD
• Newcastle Cognitive
Fluctuation Scale
Imaging Studies
• SUSPECTED-AD
• CATFieLD
Other interventional studies, costs of
dementia and information use
• PRoVIDe
• Give and Take
HTA-SADD
• Depression in dementia
• Which antidepressants effective?
• Testing mirtazapine and sertraline
• Double-blind placebo controlled trial, clinical and
cost effectiveness
• Sponsored by the Alzheimer’s Society
Recently reported –
No benefit better than placebo
www.dendron.org.uk
• Blinded Placebo controlled trial
• Memantine vs Donepezil vs
Both vs Placebo
• Severe Alzheimer’s Disease
• Follow up for 12 months
www.dendron.org.uk
Published NEJM 8th March 2012
11
42
Direction of improvement
10
40
9
38
8
36
BADLS
sMMSE
7
6
5
34
32
30
4
28
3
2
26
placebo
Direction of improvement
memantine
1
24
donepezil
donepezil and memantine
0
0
6
18
30
Visit Week
22
52
0
6
18
30
Visit Week
52
Servier Study DeNDRoN 076
Patient group - Alzheimer’s disease
PI – Dr Andrew Byrne
Recruiting across the North East
NTW, TEWV, Gateshead,
and Northumbria Trusts
• Testing an oral histamine H3 inverse
agonist
• Presynaptic H3 receptors inhibit
transmitter release - the inverse agonist
should remove the inhibition and
promote transmitter release
• Inclusion: Moderate Alzheimer’s,
MMSE 12-20, stable on 10mg donepezil
SCARLET ROAD STUDY
DeNDRoN 055
Patient group – MCI (Prodromal Alzheimer’s)
PI – Dr Bob Barber
Recruiting across the North East
NTW, TEWV, Gateshead, and Northumbria Trusts
 Subcutaneous gantenerumab (monoclonal antibody)
removes amyloid
 2 year study in MCI – reduce risk of converting to
dementia?
Inclusion: MMSE >24, age 50-85
PROVIDE - Prevalence of Visual Impairment
in People with Dementia
Patient group –
any dementia, mild, moderate or severe
Research sites – TEWV, NTW, and Northumbria
PIs – Helen Robinson, Bob Barber, and Julian Hughes
recruiting across the North East
• 100 community dwelling
•
•
•
•
•
•
100 care home residents
recruit, consent, MMSE
referred to optometrists
assess visual impairment
how visual problems are managed
recommend interventions to improve eye care
Brains for Dementia Research
Brains for Dementia Research (BDR)
• For anyone over 65 with a diagnosis of
dementia, or controls
• Annual visit, collect clinical data
Brain tissue stored in the
Newcastle Brain Tissue Resource
www.dendron.org.uk
DeNDRoN
Patient List
 Patients use the Patient List to keep informed about studies
 DeNDRoN uses the Patient List to recruit quickly to studies
 Clinicians use the Patient List to give patients research opportunities
www.dendron.org.uk
Patient List Disease Groups
VaD/AD
VaD
MCI
Alzheimer’s disease
PSP
FTD
Parkinson’s disease
PDD
Dementia with Lewy bodies
DLB
Parkinson’s disease dementia
AD
Progressive supranuclear palsy
Fronto-Temporal dementia
Vascular dementia
Mixed Vascular and Alzheimer’s dementia
Mild Cognitive Impairment
PD
Over 550 patients – half
of dementia patients
have joined a study
Clinician and Researcher
Involvement
• Refer to the Patient List
• Refer to an existing study
• Register interest in a study
recruiting elsewhere
• Develop a research proposal
www.dendron.org.uk
Public / Patient Involvement Panel
The PPI Panel brings together patients and carers affected by all
the disease groups included for clinical research by DeNDRoN
Can supply quick lay opinion on proposed studies
www.dendron.org.uk
Thank you!
Tel: 0191 2232740
www.dendron.org.uk
www.dendron.org.uk